Rhodotorula species are emerging pathogens in immunocompromised patients. We report the in vitro activities of eight antifungals against 64 Rhodotorula isolates collected in surveillance programs between 1987 and 2003. Rhodotorula strains are resistant in vitro to fluconazole (MIC at which 50% of the isolates tested are inhibited [MIC 50 ], >128 g/ml) and caspofungin (MIC 50 , >8 g/ml). Amphotericin B (MIC 50, 1 g/ml) and flucytosine (MIC 50 , 0.12 g/ml) are both active in vitro, and the new and investigational triazoles all have some in vitro activity, with ravuconazole being the most active (MIC 50 , 0.25 g/ml).Rhodotorula species, yeasts that belong to the family Cryptococcaceae, have been increasingly recognized as important human pathogens (1, 4, 7, 8, 10-12, 14, 18, 21, 23). Immunocompromised patients, particularly those with central venous catheters or other indwelling devices, are at highest risk for infection (10,14,18). While Rhodotorula strains appear to be less virulent than the more common yeast pathogens such as Candida and Cryptococcus neoformans, Rhodotorula infection has been associated with a crude mortality of up to 15% (12) and can cause sepsis syndrome and other life-threatening complications (4, 10, 13). Rhodotorula bloodstream infections have been successfully managed with line removal alone, antifungal therapy without line removal, and with a combination of these approaches (7, 10). Regarding choice of antifungal therapy, previously reported data have shown amphotericin B and flucytosine (5-FC) to have good in vitro activities and fluconazole and the echinocandins to have poor in vitro activities (2,5,6,20,23). However, most reports describe fewer than 10 organisms, not all utilize standard NCCLS methodology, and only a few report data on the newer extended-spectrum triazoles (2,5,6,23).For these reasons, we decided to examine the in vitro activities of agents against over 60 Rhodotorula isolates we have collected as part of antifungal resistance surveillance surveys since the late 1980s, utilizing standardized NCCLS methods and including new and investigational antifungal agents. To our knowledge, this represents the largest collection of clinical Rhodotorula isolates for which susceptibility test results obtained by standard NCCLS methods have been reported.Sixty-four isolates of Rhodotorula were collected between 1987 and 2003 as part of several antifungal surveillance surveys (19). Sixty (94%) were human clinical isolates, the majority (n ϭ 36 [56%]) from bloodstream (n ϭ 28) or other sterile sites (n ϭ 8). All isolates were stored as suspensions in sterile distilled water at room temperature until used in the study.Prior to testing, each isolate was subcultured at least twice on potato dextrose agar plates (Remel, Lenexa, Kans.) to ensure purity and optimal growth. We confirmed species identification by using the Vitek and API yeast identification systems (bioMerieux, Inc., Hazelwood, Mo.) supplemented by conventional methods as needed (9). Voriconazole (Pfizer), fluconazole (Pfizer...